S100A9 and myelodysplastic syndrome: Interestingly, the presence of anti-PD-1 or anti-PD-L1 blocking antibodies significantly improved the clonogenic capacity of MDS BM cells, further indicating that the S100A9-induced PD-1/PD-L1 pathway activation may directly contribute to the BM failure of MDS patients.